US regulatory status: approved. Mechanism: Glutathione precursor.
- Mechanism
- Glutathione precursor
biotech · Unresectable or metastatic conventional chondrosarcoma · Advanced or metastatic solid tumors · INBX
Inhibrx Biosciences
Inhibrx Biosciences drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
San Diego, USA HQ
2010 Founded
114 Employees
Public company Type
INBX · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2010
- Employees
- 114
- Programs
- 10
- Drugs
- 17
- Patents
- 35
Inhibrx Biosciences pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Inhibrx Biosciences drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Inhibrx Biosciences in public FDA and regional records.
-
Development asset linked to Inhibrx Biosciences in public FDA and regional records.
-
Development asset linked to Inhibrx Biosciences in public FDA and regional records.
-
Development asset linked to Inhibrx Biosciences in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Inhibrx Biosciences in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Inhibrx Biosciences in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to Inhibrx Biosciences in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Inhibrx Biosciences in public FDA and regional records.
-
Development asset linked to Inhibrx Biosciences in public FDA and regional records.
-
Development asset linked to Inhibrx Biosciences in public FDA and regional records.
-
temozolomide
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor